IN2014KN03063A - - Google Patents
Info
- Publication number
- IN2014KN03063A IN2014KN03063A IN3063KON2014A IN2014KN03063A IN 2014KN03063 A IN2014KN03063 A IN 2014KN03063A IN 3063KON2014 A IN3063KON2014 A IN 3063KON2014A IN 2014KN03063 A IN2014KN03063 A IN 2014KN03063A
- Authority
- IN
- India
- Prior art keywords
- vaccine composition
- administration
- administration regimens
- polynucleotides
- enhance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/063196 WO2014005643A1 (en) | 2012-07-05 | 2012-07-05 | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
| PCT/EP2013/064286 WO2014006191A1 (en) | 2012-07-05 | 2013-07-05 | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014KN03063A true IN2014KN03063A (pt) | 2015-05-08 |
Family
ID=48746554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3063KON2014 IN2014KN03063A (pt) | 2012-07-05 | 2013-07-05 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20150209420A1 (pt) |
| JP (1) | JP6244358B2 (pt) |
| KR (1) | KR20150038010A (pt) |
| CN (1) | CN104780937A (pt) |
| AU (1) | AU2013285398A1 (pt) |
| BR (1) | BR112014033077A2 (pt) |
| CA (1) | CA2878367A1 (pt) |
| DK (1) | DK2869841T3 (pt) |
| EA (1) | EA201492230A1 (pt) |
| ES (1) | ES2895070T3 (pt) |
| HU (1) | HUE056675T2 (pt) |
| IL (1) | IL236414A0 (pt) |
| IN (1) | IN2014KN03063A (pt) |
| LT (1) | LT2869841T (pt) |
| MX (1) | MX365391B (pt) |
| PT (1) | PT2869841T (pt) |
| SG (1) | SG11201408746XA (pt) |
| WO (2) | WO2014005643A1 (pt) |
| ZA (1) | ZA201500102B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105188745B (zh) | 2013-04-25 | 2019-10-18 | 扬森疫苗与预防公司 | 稳定化的可溶性融合前rsv f多肽 |
| EP3888676A1 (en) * | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
| SG11201701745TA (en) | 2014-09-03 | 2017-04-27 | Bavarian Nordic As | Methods and compositions for enhancing immune responses |
| KR101963985B1 (ko) | 2014-09-03 | 2019-07-31 | 버베리안 노딕 에이/에스 | 필로바이러스 감염에 대한 보호 면역을 유도하기 위한 방법 및 조성물 |
| US9630994B2 (en) | 2014-11-03 | 2017-04-25 | University Of Washington | Polypeptides for use in self-assembling protein nanostructures |
| ES2875589T3 (es) | 2015-05-15 | 2021-11-10 | Curevac Ag | Regímenes de sensibilización-refuerzo que implican la administración de al menos un constructo de ARNm |
| PL3319633T3 (pl) | 2015-07-07 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Szczepionka przeciwko rsv |
| US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
| WO2017174564A1 (en) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
| AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
| EP3452087A1 (en) * | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| JP2019523644A (ja) | 2016-05-30 | 2019-08-29 | ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． | 安定化された融合前ｒｓｖ ｆタンパク質 |
| EP3484507A1 (en) | 2016-07-15 | 2019-05-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| CN115947873A (zh) | 2017-04-04 | 2023-04-11 | 华盛顿大学 | 显示副粘病毒和/或肺炎病毒f蛋白的自组装蛋白纳米结构及其用途 |
| EP3606553A1 (en) | 2017-04-06 | 2020-02-12 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
| WO2018210871A1 (en) * | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
| WO2019053109A1 (en) | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | METHOD FOR SAFE INDUCTION OF IMMUNITY AGAINST RSV |
| SG11202003609VA (en) * | 2017-10-25 | 2020-05-28 | Nouscom Ag | Eukaryotic cell line |
| WO2019094396A1 (en) * | 2017-11-07 | 2019-05-16 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| EP3758747A1 (en) | 2018-02-28 | 2021-01-06 | University of Washington | Self-asssembling nanostructure vaccines |
| GB201910794D0 (en) * | 2019-07-29 | 2019-09-11 | Pirbright Inst | Vaccine |
| CN112220921B (zh) * | 2020-08-25 | 2022-08-16 | 北京交通大学 | 一种针对呼吸道合胞病毒感染的组合疫苗 |
| CN117304280B (zh) * | 2023-11-28 | 2024-04-16 | 江苏瑞科生物技术股份有限公司 | 一种重组rsv f蛋白及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6511845B1 (en) * | 1992-08-07 | 2003-01-28 | Alan R. Davis | Methods for producing an immune response against HIV-1 |
| US6180398B1 (en) * | 1996-07-12 | 2001-01-30 | Virogeneitics Corporation | Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| WO2005017149A1 (en) * | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| CA2553541C (en) | 2004-01-23 | 2015-04-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Chimpanzee adenovirus vaccine carriers |
| JP2009529576A (ja) * | 2006-03-10 | 2009-08-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 持続感染または潜伏感染を引き起こすウイルスに対するワクチン |
| US20070292922A1 (en) * | 2006-03-31 | 2007-12-20 | Cell Genesys, Inc. | Regulated expression of recombinant proteins from adeno-associated viral vectors |
| WO2008085502A2 (en) * | 2007-01-05 | 2008-07-17 | Inseron, Inc. | A green fluorescent protein optimized for expression with self-cleaving polypeptides |
| GB0706914D0 (en) * | 2007-04-10 | 2007-05-16 | Isis Innovation | Novel adenovirus vectors |
| US20090092635A1 (en) * | 2007-08-17 | 2009-04-09 | Wyeth | Heterologous prime-boost immunization regimen |
| CL2007002710A1 (es) * | 2007-09-20 | 2008-01-04 | Univ Pontificia Catolica Chile | Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs. |
| US7863425B2 (en) * | 2007-09-26 | 2011-01-04 | Cornell University | Compositions and methods for inhibiting Yersinia pestis infection |
| GB0823497D0 (en) * | 2008-12-24 | 2009-01-28 | Isis Innovation | Immunogenic composition and use thereof |
| JP5882741B2 (ja) | 2009-02-02 | 2016-03-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サルアデノウイルスの核酸配列及びアミノ酸配列、それを含有するベクター、並びにその使用 |
| JP2012527232A (ja) * | 2009-05-18 | 2012-11-08 | パナセア バイオテック リミテッド | 遺伝子組換え改変ワクシニアアンカラウイルス（ｍｖａ）ベースのインフルエンザ万能ワクチン |
| US9095546B2 (en) * | 2009-07-20 | 2015-08-04 | National Health Research Institutes | Human respiratory syncytial virus (RSV) vaccine |
| WO2012021730A2 (en) | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
| WO2012085936A2 (en) * | 2010-12-20 | 2012-06-28 | Panacea Biotech Ltd | Recombinant respiratory syncytial virus plasmids and vaccines |
| US9125870B2 (en) * | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
-
2012
- 2012-07-05 WO PCT/EP2012/063196 patent/WO2014005643A1/en active Application Filing
-
2013
- 2013-07-05 DK DK13734111.1T patent/DK2869841T3/da active
- 2013-07-05 IN IN3063KON2014 patent/IN2014KN03063A/en unknown
- 2013-07-05 CN CN201380044981.3A patent/CN104780937A/zh active Pending
- 2013-07-05 HU HUE13734111A patent/HUE056675T2/hu unknown
- 2013-07-05 CA CA2878367A patent/CA2878367A1/en active Pending
- 2013-07-05 US US14/408,340 patent/US20150209420A1/en not_active Abandoned
- 2013-07-05 WO PCT/EP2013/064286 patent/WO2014006191A1/en active Application Filing
- 2013-07-05 BR BR112014033077A patent/BR112014033077A2/pt not_active Application Discontinuation
- 2013-07-05 MX MX2014016119A patent/MX365391B/es active IP Right Grant
- 2013-07-05 AU AU2013285398A patent/AU2013285398A1/en not_active Abandoned
- 2013-07-05 KR KR20157003211A patent/KR20150038010A/ko not_active Application Discontinuation
- 2013-07-05 LT LTEPPCT/EP2013/064286T patent/LT2869841T/lt unknown
- 2013-07-05 PT PT137341111T patent/PT2869841T/pt unknown
- 2013-07-05 EA EA201492230A patent/EA201492230A1/ru unknown
- 2013-07-05 SG SG11201408746XA patent/SG11201408746XA/en unknown
- 2013-07-05 JP JP2015519233A patent/JP6244358B2/ja active Active
- 2013-07-05 ES ES13734111T patent/ES2895070T3/es active Active
-
2014
- 2014-12-23 IL IL236414A patent/IL236414A0/en unknown
-
2015
- 2015-01-07 ZA ZA2015/00102A patent/ZA201500102B/en unknown
-
2017
- 2017-11-01 US US15/800,245 patent/US20180256704A1/en not_active Abandoned
-
2023
- 2023-02-28 US US18/115,556 patent/US20240091338A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT2869841T (pt) | 2021-10-28 |
| US20240091338A1 (en) | 2024-03-21 |
| LT2869841T (lt) | 2021-11-25 |
| ZA201500102B (en) | 2017-09-27 |
| IL236414A0 (en) | 2015-02-26 |
| DK2869841T3 (da) | 2021-10-25 |
| WO2014005643A1 (en) | 2014-01-09 |
| HUE056675T2 (hu) | 2022-02-28 |
| ES2895070T3 (es) | 2022-02-17 |
| MX2014016119A (es) | 2015-09-23 |
| JP6244358B2 (ja) | 2017-12-06 |
| CA2878367A1 (en) | 2014-01-09 |
| US20180256704A1 (en) | 2018-09-13 |
| WO2014006191A1 (en) | 2014-01-09 |
| SG11201408746XA (en) | 2015-01-29 |
| KR20150038010A (ko) | 2015-04-08 |
| AU2013285398A1 (en) | 2015-02-05 |
| EA201492230A1 (ru) | 2015-06-30 |
| CN104780937A (zh) | 2015-07-15 |
| US20150209420A1 (en) | 2015-07-30 |
| BR112014033077A2 (pt) | 2017-08-01 |
| MX365391B (es) | 2019-05-31 |
| JP2015526403A (ja) | 2015-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014KN03063A (pt) | ||
| MX2018012166A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| PL3207053T3 (pl) | Nowe peptydy immunogenne | |
| EA201691078A1 (ru) | Терапевтические пептиды | |
| MX2012009581A (es) | Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza. | |
| DK2940135T5 (da) | Heterodimeriseret polypeptid | |
| BR112014028476A2 (pt) | fragmento imunogênico de um polipeptídeo, polinucleotídeo isolado, composição farmacêutica imunogênica, métodos para tratar uma infecção, para gerar uma resposta imune em um sujeito, e para imunizar um sujeito | |
| WO2013106834A3 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| MX2021004211A (es) | Composiciones vacuna. | |
| HK1232156A1 (zh) | 穩定化矽酸鹽組合物及其作為止汗組合物的用途 | |
| EA201391183A1 (ru) | Способы усиления иммуногенспецифических иммунных ответов при помощи векторных вакцин | |
| IL251120B (en) | Immunogenic/therapeutic glycoside preparations and their uses | |
| BR112013030395A2 (pt) | polipeptídeo, polinucleotídeo, vetor, composição imunogênica, vacina, e, uso de uma composição imunogênica | |
| HK1256033A1 (zh) | 用於刺激免疫系統的肽 | |
| TN2014000518A1 (en) | Reassortant btv and ahsv vaccines | |
| SG11201500980WA (en) | Clostridium difficile polypeptides as vaccine | |
| HK1254514A1 (zh) | 用於增强疫苗接種免疫反應的方法及組合物 | |
| EP2892554A4 (en) | HIV IMMUNOSTIMULATING COMPOSITIONS WITH RECOMBINANT EXPRESSED PILI ON BACTERIA AND CORRESPONDING METHODS | |
| EP3313384A4 (en) | THERAPEUTIC IMMUNE MODULATION USING NOBLE GAS COMPOSITIONS | |
| HK1216715A1 (zh) | 基於血紅蛋白衍生肽的新型藥物組合物 | |
| PL3077512T3 (pl) | Immunogenne kompozycje i szczepionki pochodzące od bakteryjnych białek receptora powierzchniowego | |
| MX2021006543A (es) | Vacuna. | |
| CY1124712T1 (el) | Καινοτομα σχηματα προετοιμασιας-ενισχυσης που περιλαμβανουν ανοσογονα πολυπεπτιδια που κωδικοποιουνται απο πολυνουκλεοτιδια | |
| IL267680A (en) | An immunogenic compound containing a cyaa-derivative of a polypeptide to stimulate a th1/th17-directed immune response | |
| GB201106162D0 (en) | Combination vaccine |